Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Avicanna stock price, quote, forecast and news

AVCN.TO
CA05368K1003
A2PN04

Price

0.37
Today +/-
+0
Today %
+0 %
P

Avicanna stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Avicanna stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Avicanna stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Avicanna stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Avicanna's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Avicanna Stock Price History

DateAvicanna Price
8/26/20240.37 undefined
8/23/20240.37 undefined
8/22/20240.34 undefined
8/21/20240.37 undefined
8/20/20240.34 undefined
8/19/20240.35 undefined
8/16/20240.36 undefined
8/15/20240.35 undefined
8/14/20240.34 undefined
8/13/20240.33 undefined
8/12/20240.32 undefined
8/9/20240.32 undefined
8/8/20240.32 undefined
8/7/20240.31 undefined
8/6/20240.31 undefined
8/2/20240.32 undefined
8/1/20240.29 undefined
7/31/20240.31 undefined
7/30/20240.33 undefined
7/29/20240.33 undefined

Avicanna Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Avicanna, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avicanna from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avicanna’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Avicanna. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Avicanna’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Avicanna’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avicanna’s growth potential.

Avicanna Revenue, EBIT and net profit per share

DateAvicanna RevenueAvicanna EBITAvicanna Net Income
2026e35.01 M undefined33,006.15 undefined269,655.23 undefined
2025e29.26 M undefined114,901.96 undefined735,423.3 undefined
2024e21.42 M undefined408,000 undefined2.05 M undefined
202316.79 M undefined-7.42 M undefined-8.74 M undefined
20224.05 M undefined-9.66 M undefined-14.74 M undefined
20213.27 M undefined-12.87 M undefined-16.77 M undefined
20201.57 M undefined-16.64 M undefined-32.86 M undefined
2019170,000 undefined-23.25 M undefined-21.07 M undefined
2018120,000 undefined-8.33 M undefined-7.1 M undefined
201730,000 undefined-2.59 M undefined-2.6 M undefined
20160 undefined-30,000 undefined-30,000 undefined

Avicanna Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e
000013416212935
-----200.0033.33300.0031.2538.1020.69
----100.0033.3325.0043.75---
00001117000
0-2-8-23-16-12-9-7000
-----1,600.00-400.00-225.00-43.75---
0-2-7-21-32-16-14-8200
--250.00200.0052.38-50.00-12.50-42.86-125.00--
22.2922.2922.2920.0529.441.2959.1784.71000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Avicanna Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Avicanna is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
0.091.190.070.442.520.031.190.48
000.110.3800.251.372.28
00.080.150.821.012.090.780.69
0001.61.934.093.244.54
00.050.860.71.320.90.480.47
0.091.321.193.946.787.367.068.46
00.4616.2623.1621.8114.4710.3911.99
0140005201800334
00.070001.210.030
00.1310.7311.060.50.30.171.19
003.213.210000
0003.780.56000
00.830.241.2123.3916.1610.5913.51
0.092.1231.3945.1530.1723.5217.6521.97
02.7721.4946.0357.4766.2474.8981.03
00000000
-0.03-2.05-4.51-26.53-55.26-67.79-79.11-86.6
001.332.893.812.693.845.46
00000000
-0.030.7218.3122.396.021.14-0.38-0.11
0.010.551.465.186.567.294.758.87
00000000
0.110.730.333.324.493.663.841.39
00000000
0000.221.781.252.811.71
0.121.281.798.7212.8312.211.411.97
000.011.050.160.420.40.1
003.212.170000
0003.353.262.782.351.94
003.226.573.423.22.752.03
0.121.285.0115.2916.2515.414.1514
0.09223.3237.6822.2716.5413.7713.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Avicanna provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Avicanna's financial health and stability.

Assets

Avicanna's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Avicanna must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Avicanna after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Avicanna's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (k)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
0-2-7-22-32-16-14
00001,00000
000-1-200
0001,0000-2,0001,000
00011964
0000000
0000000
0-2-4-19-13-11-7
00-3-7-100
00-7-7-200
00-3,0000-1,0001,0000
0000000
0000000
0410201299
03102717109
0005300
0000000
01,000-1,00000-1,0001,000
-0.02-2.64-8.91-26.94-15.43-12.45-7.51
0000000

Avicanna stock margins

The Avicanna margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avicanna. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avicanna.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Avicanna's sales revenue. A higher gross margin percentage indicates that the Avicanna retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Avicanna's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Avicanna's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avicanna's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avicanna. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avicanna's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Avicanna Margin History

Avicanna Gross marginAvicanna Profit marginAvicanna EBIT marginAvicanna Profit margin
2026e45.38 %0.09 %0.77 %
2025e45.38 %0.39 %2.51 %
2024e45.38 %1.9 %9.55 %
202345.38 %-44.18 %-52.07 %
202246.17 %-238.52 %-363.95 %
202141.9 %-393.58 %-512.84 %
202067.52 %-1,059.87 %-2,092.99 %
201935.29 %-13,676.47 %-12,394.12 %
201845.38 %-6,941.67 %-5,916.67 %
201745.38 %-8,633.33 %-8,666.67 %
201645.38 %0 %0 %

Avicanna Stock Sales Revenue, EBIT, Earnings per Share

The Avicanna earnings per share therefore indicates how much revenue Avicanna has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avicanna earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avicanna's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avicanna’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avicanna's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avicanna Revenue, EBIT and net profit per share

DateAvicanna Sales per ShareAvicanna EBIT per shareAvicanna Earnings per Share
2026e0.35 undefined0 undefined0 undefined
2025e0.29 undefined0 undefined0.01 undefined
2024e0.21 undefined0 undefined0.02 undefined
20230.2 undefined-0.09 undefined-0.1 undefined
20220.07 undefined-0.16 undefined-0.25 undefined
20210.08 undefined-0.31 undefined-0.41 undefined
20200.05 undefined-0.57 undefined-1.12 undefined
20190.01 undefined-1.16 undefined-1.05 undefined
20180.01 undefined-0.37 undefined-0.32 undefined
20170 undefined-0.12 undefined-0.12 undefined
20160 undefined-0 undefined-0 undefined

Avicanna business model

Avicanna Inc is a Canadian biopharmaceutical company specializing in the research, development, and manufacturing of medical marijuana products. The company was founded in 2016 by its president and CEO Aras Azadian, who has extensive experience in the pharmaceutical and biotechnology industry. The company is based in Toronto, Canada and also operates in Colombia and Switzerland. Avicanna has several subsidiaries, including Santa Marta Golden Hemp, which operates its cultivation business in Colombia. Avicanna's business model is focused on producing medical marijuana products that have better efficacy and tolerability than conventional products. The company uses a specialized process called PhytoVista™ to isolate and extract the active ingredients in plant extracts. Avicanna operates in various sectors, including the manufacturing and marketing of medical marijuana products, research and development of effective medical treatments, and collaboration with healthcare facilities and government agencies in marijuana regulation. The company offers a variety of products, including different types of hemp oil, CBD products, and pharmaceutical products such as Rho PhytoTM and Pura EarthTM. These products all share the common approach of providing patients with better, more effective, and tolerable treatment options. Rho PhytoTM is a patented medical marijuana product by Avicanna, derived from a specific cannabis strain called ACMPR. This product is approved in Canada and available as an oral solution and syringe. Rho PhytoTM is specifically tailored to meet the needs of patients with neurodegenerative diseases and has proven to be effective. Pura EarthTM is a herbal remedy derived from the medical marijuana plant and is intended to be used as an alternative medicine for pain and inflammation. In addition to manufacturing medical marijuana products, the company also conducts intensive research and development to develop medications based on synthetic cannabinoids. These substances have the potential to help patients with various conditions such as multiple sclerosis, epilepsy, and tumor diseases. Avicanna also has partnerships with various healthcare facilities and government agencies to advance the regulation of medical marijuana and ensure the safety and efficacy of these products. In summary, Avicanna is an innovative biopharmaceutical company specializing in the manufacturing and marketing of medical marijuana products. The company serves various areas within the marijuana industry, including the production of medical products, research and development, and regulation of marijuana products. With an extensive product range and a strong research and development department, Avicanna is well positioned to continue growing and developing more innovative products in the coming years. Avicanna is one of the most popular companies on Eulerpool.com.

Avicanna SWOT Analysis

Strengths

Avicanna Inc has a strong research and development team, allowing them to develop innovative cannabis-based products. This expertise gives them a competitive edge in the rapidly growing cannabis industry.

The company has secured key partnerships with reputable institutions, such as universities and research organizations. This collaboration enhances Avicanna's credibility and provides access to valuable resources.

Avicanna has a diverse product portfolio, offering a range of cannabis-based treatments and therapies for various medical conditions. This diversification helps mitigate risks associated with dependence on a single product or market segment.

Weaknesses

Avicanna Inc faces regulatory challenges in some regions where cannabis remains illegal. This limits market opportunities and may hinder the growth potential of the company.

The company relies heavily on external funding to support its operations and research activities. This dependence on financing could add financial risks and uncertainties in the long term.

Avicanna has limited brand recognition compared to some well-established players in the cannabis industry. Building a strong brand image and customer loyalty could be a challenge for the company.

Opportunities

The legalization of cannabis for medical and/or recreational use in various countries represents a significant growth opportunity for Avicanna. Expanding into new markets could drive revenue growth and market share.

Avicanna can leverage its research expertise to develop innovative cannabis-based products that cater to evolving consumer demands. This allows the company to stay ahead in a competitive market and attract a wider customer base.

The increasing acceptance and awareness of the potential medical benefits of cannabis present an opportunity for Avicanna to collaborate with healthcare professionals and expand into the pharmaceutical industry.

Threats

Intense competition within the cannabis industry poses a threat to Avicanna's market position. Competitors with greater resources and market presence may outperform the company in attracting customers and securing partnerships.

Changes in government regulations, especially regarding the legal status of cannabis and its derivatives, can have a significant impact on Avicanna's operations. Adapting to evolving regulatory environments requires agility and flexibility.

The potential negative perception of cannabis-based products by the public or medical professionals could hinder the widespread adoption and acceptance of Avicanna's offerings, limiting market growth.

Avicanna Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Avicanna historical P/E ratio, EBIT, and P/S ratio.

Avicanna shares outstanding

The number of shares was Avicanna in 2023 — This indicates how many shares 84.708 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avicanna earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avicanna's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avicanna’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avicanna's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Avicanna.

Avicanna latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2021-0.06 -0.18  (-194.12 %)2021 Q4
3/31/2021-0.04 -0.14  (-243.14 %)2021 Q1
12/31/2020-0.08 -0.18  (-120.59 %)2020 Q4
6/30/2020-0.27 -0.23  (13.27 %)2020 Q2
3/31/2020-0.09 -0.11  (-19.83 %)2020 Q1
12/31/2019-0.15 -0.34  (-122.22 %)2019 Q4
1

Avicanna list of shareholders

%
Name
Stocks
Change
Date
5.14 % Inwentash (Sheldon)5,157,55004/10/2023
4.71 % ThreeD Capital Inc4,723,3001,746,5004/10/2023
3.54 % Azadian (Aras)3,553,927560,3084/10/2023
2.10 % Char (Giancarlo Davila)2,110,34828,4414/10/2023
0.46 % Cardella (Phillip Stanley)462,434100,0002/26/2024
0.32 % McVicar (John F)318,49868,9182/26/2024
0.29 % Panchal (Chandrakant J)291,95943,1334/10/2023
0.07 % McCormack (Eileen)70,64439,6284/10/2023
0 % Palos Management Inc.0-272,0001/31/2024
0 % Hilton Capital Management, LLC0-10,0009/30/2023
1

Avicanna Executives and Management Board

Mr. Aras Azadian
Avicanna Chief Executive Officer, Director (since 2016)
Compensation 485,778
Mr. Stephen Kim
Avicanna Chief Legal Officer, General Counsel, & Corporate Secretary of Avicanna USA Inc
Compensation 414,510
Mr. Lucas Nosiglia
Avicanna President of Avicanna LATAM S.A.S.
Compensation 368,300
Mr. Phillip Cardella
Avicanna Chief Financial Officer
Compensation 265,800
Mr. John Mcvicar
Avicanna Independent Director
Compensation 97,095
1
2

Avicanna Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
MediPharm Labs Stock
MediPharm Labs
SupplierCustomer-0,600,040,350,650,90-
1

Most common questions regarding Avicanna

What values and corporate philosophy does Avicanna represent?

Avicanna Inc represents a strong commitment to innovation, integrity, and sustainability. With its focus on the development and commercialization of plant-derived pharmaceuticals, Avicanna aims to provide advanced medical solutions using cannabinoid-based therapies. The company's corporate philosophy is centered on rigorous scientific research, stringent quality control standards, and ethical practices throughout its operations. Avicanna's dedication to collaboration with healthcare professionals, regulatory compliance, and patient-centric care underscores its mission to enhance the lives of individuals with unmet medical needs. Through its pioneering efforts, Avicanna Inc strives to redefine the future of cannabinoid-based medicines.

In which countries and regions is Avicanna primarily present?

Avicanna Inc is primarily present in Canada, Colombia, and Jamaica.

What significant milestones has the company Avicanna achieved?

Avicanna Inc has achieved several significant milestones in its history. Firstly, the company successfully attained a license from the Colombian government for the cultivation of psychoactive cannabis plants. In addition, Avicanna has established strategic partnerships with leading academic institutions, such as the University of Toronto, to conduct extensive scientific research on cannabinoids. The company has also developed several innovative pharmaceutical and dermacosmetic products, leveraging its expertise in cannabinoid-based therapies. Avicanna Inc has gained international recognition for its high-quality products and innovative research, positioning itself as a prominent player in the global cannabis industry.

What is the history and background of the company Avicanna?

Avicanna Inc is a renowned Canadian biopharmaceutical company. Founded in 2016, Avicanna specializes in the development and commercialization of plant-derived cannabinoid-based products. With a mission to harness the therapeutic potential of cannabinoids, Avicanna leverages its scientific expertise in evidence-based research, pharmaceutical development, and cultivation techniques. The company operates globally and maintains partnerships with various academic institutions and multinational organizations to advance its innovations. Avicanna is recognized for its vertically integrated approach, ensuring quality control from cultivation to end products, which include pharmaceuticals, skincare, and nutraceuticals. With a commitment to scientific excellence, Avicanna remains at the forefront of the rapidly expanding cannabis industry.

Who are the main competitors of Avicanna in the market?

Some of the main competitors of Avicanna Inc in the market include Canopy Growth Corporation, Aurora Cannabis Inc, and Cronos Group Inc. These companies are also actively engaged in the cannabis industry and operate in similar markets as Avicanna Inc.

In which industries is Avicanna primarily active?

Avicanna Inc is primarily active in the cannabis and pharmaceutical industries.

What is the business model of Avicanna?

Avicanna Inc's business model revolves around the development and commercialization of pharmaceutical-grade cannabinoid-based products. The company focuses on harnessing the therapeutic potential of cannabinoids through research, collaboration, and strategic partnerships. Avicanna aims to offer innovative solutions for various medical conditions by leveraging their expertise in pharmaceutical development, cultivation, extraction, and formulation technologies. Their comprehensive portfolio includes patented and patent-pending pharmaceutical-grade formulations, derma-cosmetics, and natural health products. Avicanna Inc strives to revolutionize the global medical cannabis market by providing high-quality, evidence-based medicinal products to improve patients' lives.

What is the P/E ratio of Avicanna 2024?

The Avicanna P/E ratio is 15.32.

What is the P/S ratio of Avicanna 2024?

The Avicanna P/S ratio is 1.46.

What is the AlleAktien quality score of Avicanna?

The AlleAktien quality score for Avicanna is 4/10.

What is the revenue of Avicanna 2024?

The expected Avicanna revenue is 21.42 M CAD.

How high is the profit of Avicanna 2024?

The expected Avicanna profit is 2.05 M CAD.

What is the business model of Avicanna

Avicanna Inc is a Canadian biotechnology company in the medical and recreational cannabis industry. The company is based in Toronto and focuses on researching, developing, and manufacturing plant-based products using cannabinoids. Avicanna aims to deliver innovative products to improve the lives of patients and consumers. The company currently has three main business divisions: medical products, cosmetic products, and recreational products. In the medical field, Avicanna focuses on producing medical cannabis products for the treatment of serious illnesses such as cancer, pain, and inflammation. The company has also developed products specifically designed for women with menstrual discomfort and for patients with insomnia. In addition to medical products, Avicanna has also developed a line of advanced skincare products based on cannabinoids, specifically designed for people with skin conditions. With products such as lotions, serums, and tinctures, customers in Avicanna's cosmetic division can utilize a natural alternative for skincare based on the healing properties of cannabis. In the recreational sector, Avicanna recognizes the growing demand for cannabis products and has therefore developed products for the recreational market. Avicanna's recreational products include smoked cannabis, edible products, beverages, and oils. These products are becoming increasingly popular in the cannabis industry and can be used by customers as a legal alternative to illicit drugs. Aside from its main business divisions, Avicanna has also formed partnerships and joint ventures with other companies to spread its technology and products throughout the industry. For example, a strategic partnership with Santa Marta Golden Hemp in Colombia will allow Avicanna to produce its products and technologies at a competitive cost base and enter the South American market. Avicanna's business model is to develop medical, cosmetic, and recreational cannabis products based on the natural healing properties of cannabis. The company aims to provide natural alternatives for diseases treatment and skincare, while also serving the rapidly evolving recreational cannabis industry. Avicanna also utilizes strategic partnerships to spread its technology and products within the cannabis industry.

What is the Avicanna dividend?

Avicanna pays a dividend of 0 CAD distributed over payouts per year.

How often does Avicanna pay dividends?

The dividend cannot currently be calculated for Avicanna or the company does not pay out a dividend.

What is the Avicanna ISIN?

The ISIN of Avicanna is CA05368K1003.

What is the Avicanna WKN?

The WKN of Avicanna is A2PN04.

What is the Avicanna ticker?

The ticker of Avicanna is AVCN.TO.

How much dividend does Avicanna pay?

Over the past 12 months, Avicanna paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avicanna is expected to pay a dividend of 0 CAD.

What is the dividend yield of Avicanna?

The current dividend yield of Avicanna is .

When does Avicanna pay dividends?

Avicanna pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avicanna?

Avicanna paid dividends every year for the past 0 years.

What is the dividend of Avicanna?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avicanna located?

Avicanna is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avicanna kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avicanna from 8/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.

When did Avicanna pay the last dividend?

The last dividend was paid out on 8/27/2024.

What was the dividend of Avicanna in the year 2023?

In the year 2023, Avicanna distributed 0 CAD as dividends.

In which currency does Avicanna pay out the dividend?

The dividends of Avicanna are distributed in CAD.

All fundamentals about Avicanna

Our stock analysis for Avicanna Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avicanna Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.